Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 210-959-9 | CAS number: 626-67-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: inhalation
Administrative data
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions (non-GLP)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 979
- Report date:
- 1979
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- 1 hour exposure duration
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- 1-methylpiperidine
- EC Number:
- 210-959-9
- EC Name:
- 1-methylpiperidine
- Cas Number:
- 626-67-5
- Molecular formula:
- C6H13N
- IUPAC Name:
- 1-methylpiperidine
- Details on test material:
- - Name of test material (as cited in study report): 1-Methylpiperidin
- Physical state: liquid, yellow
- Analytical purity: ≥ 98 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- animals: Wistar rat TNO 74
- Source: Winkelmann, Borchen, Germany
- Weight at study initiation: control: males: day 0: 214.9 ± 10.83 g, females: day 0: 182.3 ± 3.34 g, 13.8 mg/L: males: day 0: 215.7 ± 13.42 g, females: day 0: 177.1 ± 7.84 g, 15.4 mg/L: males: day 0: 217.1 ± 6.26 g, females: day 0: 183.5 ± 5.99 g.
- no further data
ENVIRONMENTAL CONDITIONS
- no data
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose/head only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Using an infusion pump the aerosol was pressed into a diffuser nozzle, in which filtered compressed air is supplied additionally. The pressure at the diffuser nozzle is measured by a manometer. The mist from the diffuser nozzle enters the inhalation chamber.
- Exposure chamber volume: 36 L
- Method of holding animals in test chamber: glass tubes
- Source and rate of air: 10 L/min
- Method of conditioning air: The test substance was nebulised with dry compressed air. Thereby the test substance was mixed with water and the mixture was supplied to the nozzle.
- Method of particle size determination: Particle size distribution was determined with the concentration of 15.4 mg/L and as stray light diameter. For the concentration of 13.8 mg/L the same particle size distribution was assumed.
- Treatment of exhaust air: The condensate of the walls of the inhalation chamber is collected in a storage vessel. The aerosol is exhausted by an injection pump (8.6 L/min). 0.4 L/min are exhausted through a wash bottle to determine the concentration.
- Temperature, humidity, pressure in air chamber: 20 °C, 60 - 70 %
TEST ATMOSPHERE
- Brief description of analytical method used: Determination of the concentration was conducted during the whole inhalation duration. Withdrawal was done with 1.25 m/sec. The sample was passed through a wash bottle containing 100 mL HCl. Parts of the acid were neutralized by 1-methylpiperidine and the excess of acid was titrated back using 0.1 N NaOH. An indicator was used.
The concentration was calculated from the mass flow of liquid passing the nozzle compared to the volumetric air flow through the nozzle. The density of the substance was assumed as 1000 g/cm³.
- Samples taken from breathing zone: yes
TEST ATMOSPHERE (if not tabulated)
- Particle size distribution: < 5 µm (89.0 %); 0.5 - 1.0 µm (10.6 %); 1.0 - 3.0 µm (0.4 %) - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- 1 h
- Concentrations:
- 13.8 mg/L and 15.4 mg/L
- No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: before initiating, during and after the observation period
- Necropsy of survivors performed: yes, animals were sacrifized using urethane anaesthesia
- Other examinations performed: mortality, clinical signs, behaviour, body weight, macroscopic changes. - Statistics:
- Body weight: mean and standard deviation, U-Test Wilcoxon, Mann and Whitney.
Results and discussion
Effect levelsopen allclose all
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- 15.4 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 1 h
- Remarks on result:
- other: No mortality observed.
- Sex:
- male/female
- Dose descriptor:
- LC0
- Effect level:
- 3.85 mg/L air
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: No mortality observed. LC0 value with 1h was converted by dividing by 4 (Haber’s rule/law, dusts and mists).
- Mortality:
- No mortality was observed with both concentrations.
- Clinical signs:
- other: 13.8 mg/mL: two min after exposure start slight restlessness, and 10 min after exposure start serous discharge at the nose, and intermittent respiration was observed in single male and female animals. 20 min after start of exposure all male and female ani
- Body weight:
- Control:
males: day 0: 214.9 ± 10.83 g; day 1: 206.9 ± 9.53 g; day 2: 216.4 ± 11.1 g; day 4: 221.7 ± 11.7 g; day 7: 231.5 ± 14 g; day 8: 236.3 ± 15.94 g; day 9: 237.6 ± 15.08 g; day 10: 239.1 ± 16.39 g; day 11: 241.6 ± 16.85 g; day 14: 252.6 ± 19.75 g.
females: day 0: 182.3 ± 3.34 g; day 1: 181.4 ± 2.99 g; day 2: 181.7 ± 3.71 g; day 4: 184.7 ± 4.08 g; day 7: 188.7 ± 5.25 g; day 8: 187.8 ± 4.71 g; day 9: 189.2 ± 5.12 g; day 10: 188.1 ± 5.22 g; day 11: 188.1 ± 5.54 g; day 14: 192.1 ± 5.59 g.
13.8 mg/L:
Body weight gain was significantly reduced for males from day 1 to 8 and for females from day 1 to 7 compared to the control.
males: day 0: 215.7 ± 13.42 g; day 1: 198.6 ± 16.77 g (-4 %); day 2: 201.4 ± 18.1 g (-7 %); day 4: 211.8 ± 19.0 g (-4.5 %); day 7: 216.5 ± 20.1 g (-6.5 %); day 8: 229.2 ± 20.93 g (-4 %); day 9: 231.3 ± 21.75 g; day 10: 233.8 ± 22.33 g; day 11: 236.3 ± 23.62 g; day 14: 248.8 ± 25.59 g.
females: day 0: 177.1 ± 7.84 g (-2.9 %); day 1: 163.0 ± 10.06 g (-10 %); day 2: 163.9 ± 8.06 g (-9.8 %); day 4: 174.4 ± 11.38 g (-5.6 %); day 7: 177.5 ± 13.58 g (-5.9 %); day 8: 178.9 ± 14.46 g (-4.7 %); day 9: 182.1 ± 14.91 g (-3.7 %); day 10: 182.0 ± 13.67 g (-3.2 %); day 11: 182.4 ± 13.89 g; day 14: 185.6 ± 13.38 g.
15.4 mg/L:
Body weight gain was significantly reduced for males and females from day 1 to 9 compared to the control.
males: day 0: 217.1 ± 6.26 g; day 1: 200.1 ± 8.09 g; day 2: 202.3 ± 10.2 g; day 4: 214.0 ± 8.69 g; day 7: 225.2 ± 9.38 g; day 8: 229.2 ± 9.24 g; day 9: 232.6 ± 8.34 g; day 10: 236.8 ± 8.43 g; day 11: 237.8 ± 8.80 g; day 14: 242.2 ± 9.68 g.
females: day 0: 183.5 ± 5.99 g; day 1: 166.2 ± 7.24 g; day 2: 167.1 ± 8.86 g; day 4: 174.7 ± 6.53 g; day 7: 182.0 ± 7.90 g; day 8: 182.3 ± 6.65 g; day 9: 185.3 ± 7.02 g; day 10: 188.3 ± 8.03 g; day 11: 189.0 ± 8.67 g; day 14: 191.5 ± 6.96 g. - Gross pathology:
- No substance related abnormalities observed. Petechiae at the lung and pulmonary emphysema were observed in both, the control and the treatment group.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.